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Abstract: The production of hesperetin glycosides was investigated using glycosylation 
with  Xanthomonas campestris and cyclodextrin glucanotransferase (CGTase). X. 
campestris glucosylated hesperetin to its 3'-, 5-, and 7-O-glucosides, and CGTase 
converted hesperetin glucosides into the corresponding maltosides. The resulting 7-O-
glucoside and 7-O-maltoside of hesperetin showed inhibitory effects on IgE antibody 
production and on O2
- generation from rat neutrophils. 
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1. Introduction 
Vitamin P is the term used for bioactive flavonoids. Hesperetin (5,7,3'-trihydroxyl-4'-methoxyl-
flavanone), which occurs in Citrus species, tomatoes, and apples, is a kind of vitamin P and has been 
well documented for its medicinal properties as an important Chinese traditional medicine [1,2]. 
Hesperetin has been studied for its effects on the blood-brain barrier, signal transduction pathway, and 




certain kinds of cancer [3-6]. However, hesperetin barely dissolves in aqueous solution, and this low 
water-solubility limits its further pharmacological exploitation. 
Glycosylation is considered to be an important method for the conversion of water-insoluble and 
unstable organic compounds into the corresponding water-soluble and chemically stable derivatives. 
Recently, Mizukami et al. reported that glucosyl conjugation was far more effective than cyclodextrin 
complexation at enhancing the water solubility of hydrophobic compounds such as curcumin [7]. 
Hesperidin is a hesperetin glycoside, i.e., a 7-O-β-rutinoside of hesperetin. The values of the partition 
coefficient (logP) of hesperetin and hesperidin are 2.6 and 1.1, respectively [8]. Hesperidin is widely 
used as vitamin P2, which has biologically beneficial effects such as anticancer, antimutagenic, 
anticarcinogenic, and cholesterol-lowering activities [9-11]. Furthermore, the glycosides of hesperidin 
have been utilized in food industries as food additives (Hesperidin S (Hayashibara Biochemical 
Laboratories Ltd.)). Therefore, the glycosides of hesperetin are important from a physiological point of 
view. One-step biocatalytic glycosylation is useful for synthesis of glycosides rather than chemical 
glycosylation that requires tedious protection-deprotection procedures [7]. Herein we report the 
glycosylation of hesperetin into the corresponding glucosides and maltosides by Xanthomonas 
campestris and cyclodextrin glucanotransferase (CGTase), which has been used for production of 
Hesperidin S. We also report the inhibitory effects of hesperetin glycosides on IgE antibody formation 
and on O2
- generation from rat neutrophils. Hesperetin glycosides synthesized here may be useful food 
ingredients which have potent anti-allergic activities. 
2. Results and Discussion 
2.1. Production of Hesperetin α-glycosides 
The structure of hesperetin and the six newly synthesized vitamin P compounds are shown in Figure 
1. The glucosylation of hesperetin (1) was investigated using the lyophilized cells of X. campestris. 
Incubation of lyophilized X. campestris cells with hesperetin (1) and a sugar donor, i.e., maltose, for 
five days gave three new compounds, 3'-, 5-, and 7-O-α-glucosides of hesperetin (2-4), which were 
detected in HEPES-NaOH buffer (10 mM) by HPLC. The glucoside products 2-4 were isolated from 
n-butanol extracts of the buffer by preparative HPLC (2, 12% yield; 3, 10%; 4, 15%). The compounds 
2-4 were individually glycosylated by CGTase to give three new compounds 5-7 in 49, 62, and 50% 
yield, respectively. The chemical structures of products 5-7 were determined as hesperetin 3'-O-α-
maltoside, hesperetin 5-O-α-maltoside, and hesperetin 7-O-α-maltoside, which have not been 
identified before, by HRFABMS, 
1H and 
13C NMR, H-H COSY, C-H COSY, and HMBC spectra. 
The HRFABMS spectra of 5-7 included pseudomolecular ion [M+Na]
+ peaks at 649.1751 for 5, 
649.1755 for 6, and 649.1750 for 7  (calculated for C28H34O16Na, 649.1745), indicating that each 
product consisted of one substrate and two hexoses. The sugar components in these products were 
determined to be glucose on the basis of the chemical shifts of their carbon signals. The 
1H NMR 
spectra showed two proton signals at δ 5.01 (1H, d, J = 3.6 Hz) and 5.06 (1H, d, J = 3.2 Hz) for 5, δ 
5.03 (1H, d, J = 3.0 Hz) and 5.40 (1H, d, J = 3.2 Hz) for 6, and δ 5.05 (1H, d, J = 3.2 Hz) and 5.17 (1H, 
d, J = 3.0 Hz) for 7, indicating that the glucoside linkage in these three compounds had α-orientations. 
The HMBC spectra of 5-7 included correlations between the proton signal at δ 5.01 (H-1''') and the 




146.2 (C-3') for 5, between the proton signal at δ 5.03 (H-1''') and the carbon signal at δ 80.5 (C-4'') 
and between the proton signal at δ 5.40 (H-1'') and the carbon signal at δ 165.1 (C-5) for 6, and 
between the proton signal at δ 5.05 (H-1''') and the carbon signal at δ 80.5 (C-4'') and between the 
proton signal at δ 5.17 (H-1'') and the carbon signal at δ 166.9 (C-7) for 7. These data indicated that 5-
7 were α-maltosyl analogues of 1, the sugar moiety of which attached at their 3'-position (5), 5-
position (6), and 7-position (7). Thus, products 5-7 were identified as hesperetin 3'-O-α-maltoside (5), 
hesperetin 5-O-α-maltoside (6), and hesperetin 7-O-α-maltoside (7), respectively. The substrate 
hesperetin used for this experiment was a chiral compound, the stereochemistry of which was 2S [12-19] 
(Sigma-Aldrich Co.). On the other hand, it has been reported that hesperidin epimerizes in C2 to form the 
2S and 2R epimers [20]. The absolute configuration at C-2 of the aglycone of hesperetin α-glycosides 
synthesized here is not clarified. 
Figure 1. Synthetic route of α-glucosides and α-maltosides of hesperetin-------sequential 

































































































It has been reported that kojic acid α-glucoside was synthesized by lyophilized X. campestris in the 
presence of maltose as a sugar donor [21]. This report led us to produce new vitamin P compounds, 
that is, hesperetin α-glycosides, by lyophilized X. campestris. Six new vitamin P compounds, i.e., 
hesperetin α-glucosides and hesperetin α-maltosides, were successfully synthesized through sequential 
biocatalytic  α-glycosylation by X. campestris and CGTase. Earlier, some kinds of hesperetin β-
glycosides, such as β-glucosides, β-diglucosides, and β-rutinoside, had been isolated from fruits and 
flowers of Citrus species [22-24]. On the other hand, it has been reported that cultured cells of Citrus 
paradisi glycosylated hesperetin at its 7-position to give 7-O-β-glucoside and 7-O-β-rutinoside 
[25,26]. Compared to the β-glucosylation with C. paradisi, X. campestris showed high potential for the 
α-glucosylation at each phenolic hydroxyl groups of hesperetin to give three α-glucosides. This is the 




2.2. Anti-allergic Activity of Hesperetin α-glycosides 
The effects of hesperetin α-glucosides  2-4  and hesperetin α-maltosides  5-7 on IgE antibody 
formation were investigated by in vivo bioassay using ovalbumin as an antigen [27]. The average rat 
plasma IgE level after treatment of ovalbumin with or without test compounds was examined and the 
results are summarized in Table 1. Hesperetin  7-O-α-glucoside (4) and 7-O-α-maltoside (7) showed 
inhibitory action on IgE antibody generation. On the other hand, 3'-O-α-glycosides 2 and 5 and 5-O-α-
glycosides 3 and 6 did not inhibit IgE antibody generation. 
There is evidence that superoxide anion (O2
-), which is generated primarily through the activation 
of the plasma membrane-bound NADPH-oxidase system, is responsible for allergic reactions, and anti-
allergic drugs such as mequitazine have been reported to inhibit O2
- generation [28]. 
Table 1. Suppressive action of hesperetin α-glycosides 2-7 on IgE antibody formation. 
Compound IgE  level
a 
None  393.1 ± 188.7 
2  356.6 ± 186.9 
3  338.3 ± 163.0 
4  155.4 ± 67.2* 
5  365.7 ± 126.7 
6  374.9 ± 169.1 
7  164.6 ± 57.8* 
aThe results were expressed as average plasma IgE level of seven rats administered a total 
of 10 mg/kg of each test compound. Data are presented as mean ± SE. Asterisk indicates 
significant differences from controls (*P < 0.05). 
Table 2. Effects of hesperetin α-glycosides 2-7 on O2
- generation from rat neutrophils. 
Compound %Inhibition
a 
2  12 
3  17 
4  59 
5  5 
6  7 
7  46 
Mequitazine 62 
aThe percentage reduction of the O2
- generation was calculated as follows: %Inhibition = 
[(Pc- P t)/Pc]x100, where Pt and Pc are the photon count of sample solutions with and 
without the test compound. 
 
The effects of hesperetin α-glucosides 2-4 and hesperetin α-maltosides 5-7 on O2
- generation from 
rat neutrophils using cypridina luciferin analog-dependent chemiluminescence as a probe for O2




generation were examined according to the previously reported methods [29]. The results are 
expressed in terms of the percentage reduction of the O2
- generation. Percent inhibition was calculated 
as follows: %Inhibition = [(Pc- Pt)/Pc]x100, where Pt and Pc are the photon count of sample solutions 
with and without the test compound. As a result, inhibitory effects of hesperetin 7-O-α-glycosides 4 
and 7 and an authentic anti-allergic drug on fMLP-induced O2
- generation from rat neutrophils are as 
follows: 4, 59%; 7, 46%; mequitazine, 62% (Table 2). Particularly, hesperetin 7-O-α-glucoside (4) 
exhibited significant inhibitory activity for O2
- generation, to the same level as mequitazine. This is the 
first time that hesperetin α-glycosides have been shown to have a strong inhibitory effect on O2
- 
generation. Hesperetin 3'-O-α-glycosides 2 and 5 and hesperetin 5-O-α-glycosides 3 and 6 showed no 
inhibitory action on O2
- generation. Previously, we reported that 7-O-β-glycosides of polyphenols, i.e., 
genistein and quercetin, showed anti-allergic activities, whereas polyphenol glycosides, where the is 
attached at other phenolic hydroxyl groups, exhibited no anti-allergic actions [29]. These findings 
suggest that α-glycosides at C-7 of hesperetin did not attenuate the anti-allergic activity of the 
aglycone, i.e., hesperetin, and that phenolic hydroxyl groups at 3'- and 5-positions of hesperetin might 
be necessary for hesperetin and its glycosides to act as anti-allergic formulations. Recently, it has been 
reported that hesperetin is more bioactive than its glycoside hesperidin, and efforts to formulate 
hesperetin are in progress to improve absorption and its disposition [30-33]. The hesperetin α-
glycosides might act as pro-drugs that release hesperetin by hydrolysis in the living body. 
Recently, some β-glycosides of tocopherol (vitamin E) have been reported to act as potential anti-
allergic agents [34]. In addition, the β-glycosides of vitamin E showed inhibitory effects on O2
- 
generation from rat neutrophils. It was postulated that inhibition of O2
- generation by vitamin E β-
glycosides was responsible for their anti-allergic activity [28,34]. Studies on the mechanism by which 
the hesperetin α-glycosides synthesized here act as anti-allergic compounds are now in progress. 
3. Experimental Section 
3.1. General 
Substrate, hesperetin, was purchased from Sigma-Aldrich Co. CGTase was purchased from Amano 
Pharmaceutical Co. Ltd.  The NMR spectra were recorded in CD3OD using a Varian XL-400 
spectrometer. The chemical shifts were expressed in δ  (ppm) referring to tetramethylsilane. The 
HRFABMS spectra were measured using a JEOL MStation JMS-700 spectrometer. HPLC was carried 
out on a YMC-Pack R&D ODS column (150 x 30 mm) [solvent: CH3CN:H2O (3:17, v/v); detection: 
UV (280 nm); flow rate: 1.0 mL/min].  
3.2. Bacterial Strain and Culture Conditions 
X. campestris was a gift from the Department of Chemistry of Okayama University of Science. 
Culture medium used for growth of X. campestris had the following composition (in grams per liter): 5 
g of maltose, 3 g of peptone, 0.4 g of yeast extract, 0.2 g of MgSO4. The cells were grown in the 
culture medium with continuous shaking on a rotary shaker (120 rpm) at 30°C. 




3.3. Production of Hesperetin α-glucosides by X. Campestris 
The cultures of X. campestris were grown in 500 mL conical flasks containing 200 mL of culture 
medium at 30 °C. Prior to use for the experiments, the cells were harvested by centrifugation at 8,000 
g for 15 min and were lyophilized. Hesperetin α-glucosides were prepared as follows. A total of 2 
mmol of hesperetin was added to ten 300-ml conical flasks (0.2 mmol/flask), each of which contained 
5 g of lyophilized X. campestris cells and 1 mmol of maltose in 100 ml of 10 mM HEPES-NaOH 
buffer (pH 7.5). The mixture was incubated continuous shaking on a rotary shaker (120 rpm) for 5 
days at 30 °C. The reaction mixture was centrifuged at 8,000 g for 15 min and the supernatant was 
extracted with n-butanol. The butanol fraction was purified by preparative HPLC on YMC-Pack R&D 
ODS column to give hesperetin α-glucosides. 
3.4. Production of Hesperetin α-maltosides by CGTase 
To a solution containing 0.1 mmol of hesperetin α-glucoside and 5 g of starch in 25 mM of sodium 
phosphate buffer (pH 7.0) was added 100 U of CGTase. The reaction mixture was stirred at 40 °C for 
24 h, and then the mixture was centrifuged at 3,000 g for 10 min. The supernatant was subjected on to 
a Sephadex G-25 column equilibrated with water to remove CGTase. The fractions containing 
glycosides were purified by preparative HPLC on YMC-Pack R&D ODS column to give hesperetin α-
maltosides. 
Spectral data of selected new compounds are as follows. 
Hesperetin 3'-O-α-maltoside (5): FABMS m/z: 649.1751 [M+Na]
+; 
1H NMR (400 MHz, DMSO-d6, 
δ in ppm): δ 2.77 (1H, dd, J = 17.8, 2.8 Hz, H-3a), 3.08-3.88 (12H, m, H-2'', 2''', 3'', 3''', 4'', 4''', 5'', 5''', 
6'', 6'''), 3.33 (1H, dd, J = 17.8, 12.8 Hz, H-3b), 3.78 (3H, s, OCH3), 5.01 (1H, d, J = 3.6 Hz, H-1'''), 
5.06 (1H, d, J = 3.2 Hz, H-1''), 5.50 (1H, dd, J = 12.6, 2.8 Hz, H-2), 5.89 (1H, d, J = 2.8 Hz, H-6), 5.90 
(1H, d, J = 2.8 Hz, H-8), 7.03 (1H, dd, J = 8.4, 2.0 Hz, H-6'), 7.08 (1H, d, J = 8.4 Hz, H-5'), 7.25 (1H, 
d, J = 2.0 Hz, H-2'); 
13C NMR (100 MHz, DMSO-d6, δ in ppm): δ 43.3 (C-3), 55.5 (OCH3), 60.5 (C-
6'''), 60.7 (C-6''), 69.5 (C-4'''), 72.2 (C-5''), 72.4 (C-2''), 73.5 (C-2''', C-3''), 73.9 (C-3''', C-5'''), 78.0 (C-
2), 80.7 (C-4''), 94.7 (C-8), 95.7 (C-6), 98.0 (C-1''), 100.5 (C-1'''), 101.4 (C-10), 111.5 (C-5'), 113.6 (C-
2'), 120.5 (C-6'), 130.2 (C-1'), 146.2 (C-3'), 149.0 (C-4'), 162.4 (C-9), 163.2 (C-5), 166.3 (C-7), 196.9 
(C-4). 
Hesperetin 5-O-α-maltoside (6): FABMS m/z: 649.1755 [M+Na]
+; 
1H NMR (DMSO-d6): δ 2.76 
(1H, dd, J = 17.8, 2.8 Hz, H-3a), 3.05-3.89 (12H, m, H-2'', 2''', 3'', 3''', 4'', 4''', 5'', 5''', 6'', 6'''), 3.33 (1H, 
dd, J = 17.8, 12.8 Hz, H-3b), 3.78 (3H, s, OCH3), 5.03 (1H, d, J = 3.0 Hz, H-1'''), 5.40 (1H, d, J = 3.2 
Hz, H-1''), 5.51 (1H, dd, J = 12.6, 2.8 Hz, H-2), 6.08 (1H, d, J = 2.8 Hz, H-6), 6.12 (1H, d, J = 2.8 Hz, 
H-8), 6.90 (1H, dd, J = 8.4, 2.0 Hz, H-6'), 7.00 (2H, m, H-2', 5'); 
13C NMR (DMSO-d6): δ 43.0 (C-3), 
55.5 (OCH3), 60.3 (C-6'''), 60.6 (C-6''), 69.5 (C-4'''), 72.2 (C-5''), 72.5 (C-2''), 73.5 (C-2''', C-3''), 74.1 
(C-3''', C-5'''), 78.0 (C-2), 80.5 (C-4''), 93.7 (C-8), 94.8 (C-6), 99.7 (C-1''), 100.6 (C-1'''), 103.5 (C-10), 
111.7 (C-5'), 113.8 (C-2'), 117.7 (C-6'), 130.8 (C-1'), 146.0 (C-3'), 147.7 (C-4'), 162.5 (C-9), 165.1 (C-
5), 165.0 (C-7), 198.9 (C-4). 
Hesperetin 7-O-α-maltoside (7): FABMS m/z: 649.1750 [M+Na]
+; 
1H NMR (DMSO-d6): δ 2.76 
(1H, dd, J = 17.8, 2.8 Hz, H-3a), 3.07-3.83 (12H, m, H-2'', 2''', 3'', 3''', 4'', 4''', 5'', 5''', 6'', 6'''), 3.32 (1H, 




Hz, H-1''), 5.49 (1H, dd, J = 12.6, 2.8 Hz, H-2), 6.16 (1H, d, J = 2.8 Hz, H-6), 6.22 (1H, d, J = 2.8 Hz, 
H-8), 6.88 (1H, dd, J = 8.4, 2.0 Hz, H-6'), 6.92 (2H, m, H-2', 5'); 
13C NMR (DMSO-d6): δ 42.2 (C-3), 
55.5 (OCH3), 60.4 (C-6'''), 60.6 (C-6''), 69.5 (C-4'''), 72.2 (C-5''), 72.5 (C-2''), 73.8 (C-2''', C-3''), 74.1 
(C-3''', C-5'''), 78.2 (C-2), 80.5 (C-4''), 95.4 (C-6), 95.9 (C-8), 100.1 (C-1''), 100.7 (C-1'''), 103.2 (C-
10), 111.5 (C-5'), 113.9 (C-2'), 117.6 (C-6'), 130.7 (C-1'), 146.0 (C-3'), 147.8 (C-4'), 162.2 (C-9), 162.7 
(C-5), 166.9 (C-7), 196.7 (C-4). 
3.5. Suppressive Action on IgE Antibody Formation 
The inhibitory action of hesperetin α-glycosides on IgE antibody formation was examined as 
follows. Ovalbumin was used as the antigen (1 mg/rat), and Al(OH)3 and pertussis vaccine were used 
as the adjuvants (20 mg and 0.6 mL/rat, respectively). Sensitization was made by injecting a mixture 
(0.6 mL) of the antigen and the adjuvant into the paws of each rat (male, ca. 200 g). Paw edema was 
measured 24 h after injection and the treated rats were divided in groups with an equal average 
swelling volume. Each sample was dissolved in physiological saline containing 10% Nikkol and the 
solution was injected daily into the rat for 11 days starting on the day of grouping. The amount of IgE 
was measured by the passive cutaneous anaphylaxis method on the 15th day [27]. The results were 
expressed as average of plasma IgE level of seven rats administered a total of 10 mg/kg of each test 
compound. 
3.6. Inhibitory Action on O2
- Generation from Rat Neutrophils 
Effects of hesperetin α-glycosides on O2
- generation from rat neutrophils were examined as follows.   
Male Wistar rats, each weighing 250 to 300 g, were used. Under ether anesthesia, whole blood was 
collected from the carotid artery and diluted twice with Hanks' balanced salt solution (HBSS) (pH 7.4). 
Neutrophils were purified by Percoll density gradient centrifugation. O2
- generation from rat 
neutrophils was measured by the cypridina luciferin analog-dependent chemiluminescence method 
[28]. An authentic antiallergic agent, mequitazine, was used as a positive control. Neutrophil 
suspensions (10
6 cells/mL) were incubated for 3 min in HBSS containing 0.4 mM of cypridina 
luciferin analog and 50 μM of hesperetin α-glycoside or authentic antiallergic agent at 37 °C in the 
dark. Five seconds later, N-formyl-Met-Leu-Phe (fMLP) (2.5 μM) was added into the assay mixture. 
Cypridina luciferin analog-dependent chemiluminescence was monitored with a Lumicounter ATP-
237 (Advantec Co. Ltd.). The results are expressed in terms of the percentage reduction of the O2
- 
generation from rat neutrophils at 5 min after the administration of fMLP by test compounds. 
4. Conclusions 
Hesperetin  α-glycosides,  i.e.,  α-glucosides and α-maltosides, were successfully synthesized 
through sequential biocatalytic glycosylation by X. campestris and CGTase for the first time. It should 
be emphasized that new vitamin P glycosides, i.e., hesperetin α-maltosides, which are glycosylated at 
each phenolic hydroxyl group of hesperetin, can be prepared by the present two-step glycosylation 
system. Hesperetin 7-O-α-glucoside and hesperetin 7-O-α-maltoside showed suppressive action on 
IgE antibody formation and exhibited inhibitory effects on O2




new vitamin P compounds would be useful food ingredients with potent anti-allergic activities. Further 
studies on the physiological activity of hesperetin α-glycosides, such as cytotoxicity and anticancer 
activity, are now in progress. 
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